Uback rankings
How the AI ranks →| Ranking | Tier | Rank | Edition | Next update |
|---|---|---|---|---|
| Telemedicine · worldwide | Top 10 | #10 | Edition 0 (beta) · Sep 2026 | 2 Jan 2027 |
Estimated valuation
AI · Telemedicine ranking (worldwide)- Anchor
- Last known equity round: Series C · USD 58.7M (USD 65.7M with extension) · Aug 2021
An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method
Funding history
| Date | Round | Amount | Type | Investors | Source |
|---|---|---|---|---|---|
| Aug 2021 | Series C | USD 58.7M (USD 65.7M with extension) | Equity | Asia Partners, Novo Holdings | dealstreetasia.com |
Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.
Independent analyses
By industry professionals & analystsIndustry professionals and financial analysts can publish their own analysis of Doctor Anywhere as a PDF, on one of three angles only:
Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.
Comparable companies in telemedicine
Full telemedicine ranking →Investors in Doctor Anywhere: Asia Partners · Novo Holdings
Sources. dealstreetasia.com · cbinsights.com
Last updated: Sep 2026Report an error
Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.